Lecithin
- Generic Name
- Lecithin
- Drug Type
- Small Molecule
- CAS Number
- 8002-43-5
- Background
A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
- Indication
用于脂肪肝、动脉粥样硬化等疾病的辅助治疗。
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
- Conditions
- Drug Induced Liver Injury
- Interventions
- Procedure: Plaslna exchangeProcedure: Liver transplantation
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 232
- Registration Number
- NCT06922669
- Locations
- 🇨🇳
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning, China
Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area
- Conditions
- Healthy
- Interventions
- Drug: Matching placebo of AYP-101
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- AMIpharm Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT06256445
- Locations
- 🇰🇷
Chung-Ang University Hosptial, Seoul, Heukseok-ro, Dongjak-gu, Korea, Republic of
Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects
- Conditions
- Healthy SubjectsSubmental Fat
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- AMIpharm Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05476094
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Bundang-gu, Seongnam-si,, Korea, Republic of
Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- AMIpharm Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05266729
- Locations
- 🇰🇷
Chung Ang University Hospital, Seoul, Korea, Republic of
The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI
- Conditions
- Drug-Induced Acute Liver Injury
- Interventions
- Drug: bicyclol, 25mg/ tablet
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Drug Induced Liver Disease Study Group
- Target Recruit Count
- 360
- Registration Number
- NCT05063500
- Locations
- 🇨🇳
Renji Hospital ，Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳905th Hospital of Pla Navy, Shanghai, Shanghai, China
Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury
- Conditions
- Acute Drug Induced Liver Injury
- Interventions
- Drug: Magnesium Isoglycyrrhizinate injection 200 mg QD
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 73
- Registration Number
- NCT04595916
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- AMIpharm Co., Ltd.
- Target Recruit Count
- 143
- Registration Number
- NCT03982225
- Locations
- 🇰🇷
Yonsei University Health System, Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI
- Conditions
- Drug-Induced Acute Liver Injury
- Interventions
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Drug Induced Liver Disease Study Group
- Target Recruit Count
- 244
- Registration Number
- NCT02944552
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis
- Conditions
- Hepatitis, Autoimmune
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Xiaoli Fan
- Registration Number
- NCT02878863
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- Prometheus Laboratories
- Target Recruit Count
- 25
- Registration Number
- NCT02849951
- Locations
- 🇺🇸
Prometheus Site 42, Lancaster, California, United States
🇺🇸Prometheus Site 35, Clearwater, Florida, United States
🇺🇸Prometheus Site 53, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.